ReviewJournal of clinical medicine2022
A Review of Selective Laser Trabeculoplasty: "The Hype Is Real".
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Short-Term Stability of Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness Following Direct Selective Laser Trabeculoplasty in Patients with Ocular Hypertension and Glaucoma.Diagnostics (Basel, Switzerland) · 2026Article
- Efficacy and safety of the VISULAS green with option selective laser trabeculoplasty in pseudoexfoliative syndrome glaucoma and pseudoexfoliative syndrome ocular hypertension.International journal of ophthalmology · 2026Article
- One-year outcomes of selective laser trabeculoplasty for open-angle glaucoma in Indian eyes.Indian journal of ophthalmology · 2025Article
- The Relationship of Frailty with Surgical and Laser Treatment for Patients with Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Cost-effectiveness of selective laser trabeculoplasty as a replacement for hypotensive eye drops in the Brazilian public health system.Clinics (Sao Paulo, Brazil) · 2025Article
- Adopting Interventional Glaucoma Via Sustained-Release Therapies: The Wide-Ranging Impact of Procedural Pharmaceuticals in Ophthalmology.Ophthalmology and therapy · 2024Article
- Nanomedicine in glaucoma treatment; Current challenges and future perspectives.Materials today. Bio · 2024Review
- Article
- Outcomes of Micropulse Laser Trabeculoplasty Compared to Selective Laser Trabeculoplasty: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Mechanism of selective laser trabeculoplasty: a systemic review.International journal of ophthalmology · 2024Review
- Estimation of Topical Glaucoma Medication Over-Prescription and Its Associated Factors.Journal of clinical medicine · 2023Article
- Nationwide Analysis of Glaucoma Surgeries in Fiscal Years of 2014 and 2020 in Japan.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presently, there is no efficacious treatment for glaucomatous optic neuropathy; the current treatment is focused on lowering intraocular pressure (IOP). Studies have demonstrated the safety and efficacy of selective laser trabeculoplasty (SLT) in reducing the IOP in eyes with open-angle (OAG) glaucoma or ocular hypertension (OH). Moreover, the European Glaucoma Society has instated SLT as the first-line or adjunctive treatment in OAG or OH, reiterating its clinical significance. In this review, we outline the old and the new roles of SLT, with an emphasis on clinical practice, and look further into its renewed appeal and future developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.